CD8A and neoplasm: Some studies have reported that erythroid progenitor cells (EPCs) derived from tumor-induced EMH suppress CD8+ T-cell function, thereby impairing antitumor immunity and the efficacy of immunotherapy and promoting tumor growth [11,17,18].